Compass Therapeutics Inc Dossier - Source-backed chat

Compass Therapeutics Inc

CMPXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.87

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.90Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $162.3M

Enterprise Value $136.7M

Shares Outstanding 206M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Compass Therapeutics presents a highly binary risk/reward profile following its April 2026 clinical update. While its lead bispecific antibody, tovecimig (CTX-009), met its primary endpoint of Overall Response Rate (17.1% vs 5.3%) and key secondary endpoint of Progression-Free Survival (4.7 vs 2.6 months) in second-line biliary tract cancer, it failed to show a statistically significant benefit in Overall Survival (8.9 vs 9.4 months). This OS failure, heavily confounded by a 54% patient crossover rate, led to a precipitous stock decline of over 60% and heightened regulatory uncertainty. Although the company maintains a robust cash runway of $195 million extending into 2028, the near-term valuation is entirely dependent on upcoming FDA discussions regarding the viability of a BLA submission without a pre-approval confirmatory trial.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets12 analysts · as of 18 Aug 2026

Low · most bearish analyst$5.00

Mean target$8.92

High · most bullish analyst$24.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.5015%

The FDA rejects the BLA filing package outright, citing the negative numerical OS trend (8.9 months vs 9.4 months) and requiring a fully completed Phase 3 trial prior to regulatory submission. This pushes any potential commercialization timeline past 2029, forcing Compass to burn through its cash reserves on a costly new trial and severely depressing the valuation of its early-stage pipeline.

Base CaseCentral scenario

$3.0050%

The FDA engages in constructive discussions but expresses reservations regarding the lack of OS benefit. Compass is permitted to file the BLA but may face a prolonged review cycle or be required to initiate a well-defined confirmatory trial (e.g., in the first-line setting or in geographies without crossover) as a condition for accelerated approval. The stock trades sideways as the regulatory timeline stretches, supported by the cash runway into 2028.

Bull CaseUpside scenario

$7.0035%

The FDA recognizes the confounding impact of the 54% crossover rate on Overall Survival and accepts a rolling BLA submission for tovecimig based on the robust PFS (HR=0.44) and tripled ORR. Tovecimig receives priority review and accelerated or full approval in late 2027, capturing a significant share of the underserved second-line biliary tract cancer market. Concurrently, early expansion data for CTX-8371 and CTX-10726 validate the broader bispecific platform.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong PFS benefit (HR=0.44, 56% risk reduction) and tripled ORR (17.1% vs 5.3%) in a hard-to-treat oncology indication with high unmet need.
Robust balance sheet with $195 million in cash and marketable securities as of Q1 2026, providing a runway into 2028 and covering all ongoing clinical trials.
Differentiated bispecific pipeline (CTX-8371, CTX-10726) targeting validated immune-oncology pathways in post-checkpoint inhibitor settings.

Key Investment Risks

Regulatory rejection or delay due to the failure of the COMPANION-002 trial to meet its secondary Overall Survival endpoint.
High clinical development risk inherent to early-stage assets (CTX-8371, CTX-10726, CTX-471) which have yet to show large-scale registrational efficacy.
Pre-commercial status with zero product revenue, making the company entirely dependent on capital markets or partnerships for long-term funding.

Thesis Invalidation Triggers

FDA formal refusal to file or complete review of the tovecimig BLA without a completed pre-market confirmatory trial.
Severe safety signals or dose-limiting toxicities emerging from the CTX-8371 or CTX-10726 clinical trials.
Quarterly cash burn accelerating significantly beyond the current ~$14-18 million rate, shortening the runway to below mid-2027.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.